Treatment of Wegener's Granulomatosis With Cyclophosphamide
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 200
- Locations
- 1
Study Overview
Brief Summary
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Detailed Description
The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Age Range: greater than 1 year
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •include: peripheral and central nervous system disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal organs.
- •No women who are pregnant or intend to become pregnant.
- •No patients who have known malignancies.
- •Patients must be HIV negative.
Exclusion Criteria
- Not provided
Arms & Interventions
Untitled Study
Intervention: cyclophosphamide (Drug)